ED 1612Alternative Names: ED-1612
Latest Information Update: 17 Aug 2007
At a glance
- Originator Sosei R&D
- Class Analgesics
- Mechanism of Action Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 30 Aug 2005 Arakis has been acquired by Sosei
- 04 Dec 2003 Clinical trials in Pain in United Kingdom (PO)